Tag: IHL
Incannex Healthcare’s IHL-42X lowered apnoea hypopnea index score in OSA sufferers during clinical study
Incannex Healthcare (ASX: IHL) has found its drug IHL-42X reduced the apnoea hypopnea index (AHI) score at the three doses it was given to obstructive sleep apnoea (OSA) patients during a phase 2 clin...
Incannex meets with US FDA on development of IHL-42X to treat obstructive sleep apnoea
Clinical-stage cannabinoid pharmaceutical development company Incannex Healthcare (ASX: IHL) has completed a pre-investigational new drug application (pre-IND) meeting with the US Food and Drug Admini...
Incannex Healthcare closes in on completing APIRx Pharmaceuticals acquisition
Incannex Healthcare (ASX: IHL) has completed the share sale and purchase agreement to acquire APIRx Pharmaceuticals, which will form “the world’s largest portfolio” of patented medicinal cannabinoid (...
Pre-clinical study shows Incannex Healthcare’s IHL-216A rapidly restores spatial memory after sports-related concussion
Clinical stage pharmaceutical company Incannex Healthcare (ASX: IHL) has confirmed its drug candidate IHL-216A has been observed to have a strong neuroprotective effect in a widely known model of spor...
Incannex’s psychedelic developments lead progress in March quarter
Incannex Healthcare (ASX: IHL) has released its March quarter (Q3 FY2022) results this week, unveiling significant progress in the company’s psychedelic-based and cannabinoid combination therapeutics ...
Incannex Healthcare to acquire APIRx Pharmaceuticals for 22 projects and big patent portfolio
Incannex Healthcare (ASX: IHL) has announced it will acquire APIRx Pharmaceuticals USA in an all scrip (share consideration) deal to affirm its position as a global leader in the fields of cannabinoid...
Incannex sees up to 91.5% reduction in OSA severity in preliminary IHL-42X clinical trial results
Incannex Healthcare (ASX: IHL) has completed a preliminary analysis of data from a phase 2 clinical trial investigating novel cannabinoid combination drug IHL-42X for the treatment of obstructive slee...
Incannex Healthcare partners with Monash University to develop virtual reality psychedelic treatment for anxiety disorders
Clinical-stage medicinal cannabis and psychedelic pharmaceutical company Incannex Healthcare (ASX: IHL) has secured a licence agreement with Victoria’s Monash University to develop a novel treatment f...
Incannex Healthcare makes Nasdaq Global Market debut
Clinical-stage medical cannabis and psychedelic pharmaceutical company Incannex Healthcare (ASX: IHL) has made its debut on the US-based Nasdaq Global Market using American Depositary Shares (ADS) to ...
Incannex uses December quarter to pursue development of lead drugs for unmet medical needs
Clinical stage pharmaceutical development company Incannex Healthcare (ASX: IHL) has spent the December quarter pursuing the development of its lead drugs and therapies for patients with unmet medical...
Incannex Healthcare completes dosing in phase two proof-of-concept trial of IHL-42X for obstructive sleep apnoea
Cannabinoid and psychedelics biotech Incannex Healthcare (ASX: IHL) has completed dosing of participants in its phase two proof-of-concept clinical trial of IHL-42X for the treatment of obstructive sl...
Incannex Healthcare to pursue US public offering and Nasdaq listing next month
Incannex Healthcare (ASX: IHL) has announced it is targeting a public offering and Nasdaq listing of American Depositary Shares in the United States next month.
The company revealed today it has ad...
Incannex Healthcare receives pre-IND guidance and ethics approval to begin phase 2a psychedelic trial
Psychedelic and cannabinoid biotech company Incannex Healthcare (ASX: IHL) has received ethics approval to proceed with a phase 2a psilocybin-assisted psychotherapy clinical trial for patients with cr...
Incannex Healthcare moves forward with soft gel capsule design for IHL-42X to treat obstructive sleep apnoea
Cannabinoid and psychedelic biotech company Incannex Healthcare (ASX: IHL) has engaged pharmaceuticals manufacturer Procaps SA to develop a soft gel capsule form of its IHL-42X cannabinoid drug for th...
Incannex Healthcare raises close to $18m, including $8m from chief medical officer
Clinical-stage cannabinoid and psychedelics medicine developer Incannex Healthcare (ASX: IHL) has announced it has raised almost $18 million via the completion of option exercises.
A total of 118 m...
Incannex Healthcare proposes US IPO and Nasdaq listing
Clinical-stage pharmaceutical development company Incannex Healthcare (ASX: IHL) has filed a registration statement with the United States Securities and Exchange Commission (SEC) relating to a propos...
Incannex Healthcare submits proposals for phase two psychedelics study to treat generalised anxiety disorder
Clinical-stage pharmaceutical development company Incannex Healthcare (ASX: IHL) has completed a Human Research Ethics Committee submission for a phase 2a Psi-GAD study, which combines the administrat...
Incannex Healthcare begins clinical trial using IHL-675A soft gel capsules
Clinical stage cannabinoid and psychedelic medicine development company Incannex Healthcare (ASX: IHL) has started a phase 1 clinical trial assessing a soft gel capsule formulation of its multi-use dr...
Incannex files patent application for IHL-42X and receives ethics approval for open label extension
Clinical stage cannabinoid and psychedelic development company Incannex Healthcare (ASX: IHL) has filed an international patent application as part of the development program for its drug IHL-42X for ...
Incannex Healthcare appoints Procaps to develop capsule formulations for drug IHL-675A
Specialised pharmaceutical manufacturer Procaps SA has been engaged by Incannex Healthcare (ASX: IHL) to develop the specific formulation for its drug IHL-675A using Procaps’ Unigel capsule technology...
Incannex Healthcare to develop IHL-216A formulation for traumatic brain injury clinical trials
Cannabinoid development company Incannex Healthcare (ASX: IHL) has announced it has engaged drug manufacturer Vectura Limited to develop the specific formulation required for clinical trials of IHL-21...
